In the interest of studying a homogenous sample population, in our patient cohort of 77 patients with GBM, we excluded patients that did not receive standard of care therapy, and excluded patients whose tumors had a mutation in IDH1/2, which is associated with prolonged OS [56,57]. The gene discussed is IDH1; the disease is glioblastoma.